Warby Parker slides as year-end tech pullback cools the “Santa Claus” trade
29 December 2025
2 mins read

Warby Parker slides as year-end tech pullback cools the “Santa Claus” trade

NEW YORK, December 29, 2025, 11:55 ET — Regular session

  • Warby Parker shares fell about 3% in late morning trading, tracking a broader pullback from last week’s rally.
  • Investors kept a close eye on thin year-end volumes and incoming Fed signals that could sway risk appetite.
  • Attention remains on the company’s planned AI smart-glasses tie-up with Google and the next earnings update.

Warby Parker Inc shares fell about 3% on Monday, extending a late-December pullback as U.S. stocks eased from record highs. The eyewear retailer was down 3.1% at $23.43 at 11:55 a.m. ET.

The move came as Wall Street opened the final trading week of 2025 on the back foot, with heavyweight technology stocks giving up some of last week’s gains. Consumer discretionary shares were also under pressure, according to Reuters. Reuters

That matters now because liquidity is thinning into year-end, which can amplify swings in single names. Traders are also watching whether the so-called “Santa Claus rally” — the tendency for stocks to rise late in December and early January — holds up into the new year. Reuters

Warby Parker has traded between $23.21 and $24.62 on Monday after opening at $24.17, LSEG data showed. The company has a market value of about $3.4 billion.

There were no fresh company-specific headlines on the Reuters feed for Warby Parker in recent days, after a burst of attention earlier this month tied to its push into smart eyewear. Reuters

On Dec. 9, Warby Parker said it was teaming up with Alphabet’s Google to develop lightweight, AI-powered smart glasses, with a first product expected in 2026. Google said the effort would use its Android XR platform and Gemini AI model, and described two device types — one for screen-free assistance and another with an in-lens display. Reuters

The partnership drops Warby Parker into a crowded wearables race led by Meta’s Ray-Ban smart glasses with EssilorLuxottica, while other tech giants are also circling the category, Reuters has reported. Reuters

Broader market sentiment remained a headwind on Monday as investors rotated out of mega-cap tech after a strong run. “It’ll turn out to be a buying opportunity,” said Hank Smith, director and head of investment strategy at Haverford Trust, referring to the day’s tech-led wobble. Reuters

For Warby Parker, that backdrop matters because the stock’s recent narrative has been increasingly linked to technology and “AI-adjacent” themes, even as its core business remains selling prescription and non-prescription eyewear.

On the calendar, investors will watch for U.S. economic signals that can shift rate expectations in a holiday-thinned week, including minutes from the Federal Reserve’s last meeting and weekly jobless claims. U.S. markets are closed on Thursday for New Year’s Day. Reuters

Company-specific catalysts are thinner in the near term. Zacks Investment Research lists Warby Parker’s next earnings report for Feb. 26, 2026, though the company has not detailed what incremental financial contribution, if any, it expects from smart glasses before launch. Zacks

For now, traders are watching whether Warby Parker can stabilize near the low end of Monday’s range as the year-end tape settles — and whether the next leg higher, if it comes, is driven by fundamentals like sales trends and margins rather than headline momentum.

Stock Market Today

  • Is Pediatrix Medical Group (MD) Undervalued After Nearly 58% One-Year Gain?
    January 18, 2026, 7:04 PM EST. Pediatrix Medical Group's stock surged 57.9% over the past year, trading recently near $21.86. Despite this strong run, a discounted cash flow model estimates an intrinsic value of about $37.38 per share, implying the stock could be 41.5% undervalued. The model uses projected free cash flows extending to 2035, analyzing forecasted cash flow growth. Simply Wall St's valuation framework scores Pediatrix 5 out of 6 for undervaluation potential. Investors reassessing specialized healthcare providers amid this rally may find value opportunities as the share price reflects improved sentiment but remains below longer-term intrinsic value estimates.
Linde stock edges higher as tech retreat drags Wall Street in thin year-end trade
Previous Story

Linde stock edges higher as tech retreat drags Wall Street in thin year-end trade

Mastercard slips in thin year-end trade as investors eye Fed minutes
Next Story

Mastercard slips in thin year-end trade as investors eye Fed minutes

Go toTop